Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : MediWound
Deal Size : Undisclosed
Deal Type : Collaboration
MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
Details : Under the collaboration, Mölnlycke will provide Mepilex® Up, its most recent line extension to its global market leading brand, along with Exufiber® and Exufiber® Ag dressings to be used during MediWound's upcoming Phase III study of EscharEx (EX-02)...
Product Name : EscharEx
Product Type : Enzyme
Upfront Cash : Undisclosed
August 15, 2023
Lead Product(s) : Bromelain Enriched Proteolytic Enzyme
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : MediWound
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : BioScience Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2021
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : BioScience Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : BioScience Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2020
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : BioScience Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2020
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Silver Sulfate
Therapeutic Area : Dermatology
Study Phase : Phase IV
Recipient : University Hospital, Clermont-Ferrand
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Mepilex Border Dressing
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2019
Lead Product(s) : Silver Sulfate
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Recipient : University Hospital, Clermont-Ferrand
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mepilex AG
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mepilex Ag Versus Silver Sulfadiazine in Children and Adults With Burn Injuries.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 22, 2011
Lead Product(s) : Mepilex AG
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable